Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Kamada, retaining the price target of $11.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Fein has given his Buy rating due to a combination of factors that highlight Kamada’s potential for growth and strategic development. One of the key reasons is the anticipated interim Phase 3 data from the inhaled AAT program, which is expected to be a significant decision point for the company. Although there are challenges with trial enrollment, the management’s efforts to expedite recruitment and their strategic focus on expanding plasma collection centers in the U.S. are seen as positive steps.
Furthermore, Kamada’s active pursuit of business development opportunities, including potential in-licensing, collaborations, or acquisitions by early 2026, is expected to enhance their market portfolio. The company’s recent financial performance, with a notable increase in revenues and adjusted EBITDA, underscores the successful marketing of their diverse product portfolio. These elements combined suggest a robust growth trajectory for Kamada, justifying the Buy rating.
According to TipRanks, Fein is a 5-star analyst with an average return of 24.9% and a 52.49% success rate. Fein covers the Healthcare sector, focusing on stocks such as Alector, Wave Life Sciences, and Palvella Therapeutics.
In another report released on November 3, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a ILA2,519.00 price target.